Chemotherapy-Induced Takotsubo Cardiomyopathy

Smith, Sakima A.; Auseon, Alex J.

doi:10.1016/j.hfc.2012.12.009

Cited by 50 publications

(35 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The chemotherapeutics notoriously associated with angina and ACS are 5‐Fluorouracil (5‐FU) and its oral pro‐drug capecitabine . The drug 5‐FU triggers abnormal vasoreactivity immediately after the initiation of therapy , which might be due to endothelial damage and alterations in molecular signaling pathways that control vascular smooth muscle cell tone . Although myocardial ischemia and arrhythmias are often reversible upon treatment discontinuation, lethal outcomes have been reported.…”

Section: Mechanisms Of Vascular Toxicities In Cancer Patientsmentioning

confidence: 99%

SCAI Expert consensus statement: Evaluation, management, and special considerations of cardio‐oncology patients in the cardiac catheterization laboratory (endorsed by the cardiological society of india, and sociedad Latino Americana de Cardiologıa intervencionista)

Iliescu

Grines

Herrmann

et al. 2016

Cathet Cardio Intervent

183

135

View full text Add to dashboard Cite

In the United States alone, there are currently approximately 14.5 million cancer survivors, and this number is expected to increase to 20 million by 2020. Cancer therapies can cause significant injury to the vasculature, resulting in angina, acute coronary syndromes (ACS), stroke, critical limb ischemia, arrhythmias, and heart failure, independently from the direct myocardial or pericardial damage from the malignancy itself. Consequently, the need for invasive evaluation and management in the cardiac catheterization laboratory (CCL) for such patients has been increasing. In recognition of the need for a document on special considerations for cancer patients in the CCL, the Society for Cardiovascular Angiography and Interventions (SCAI) commissioned a consensus group to provide recommendations based on the published medical literature and on the expertise of operators with accumulated experience in the cardiac catheterization of cancer patients. © 2016 Wiley Periodicals, Inc.

show abstract

Section: Mechanisms Of Vascular Toxicities In Cancer Patientsmentioning

confidence: 99%

SCAI Expert consensus statement: Evaluation, management, and special considerations of cardio‐oncology patients in the cardiac catheterization laboratory (endorsed by the cardiological society of india, and sociedad Latino Americana de Cardiologıa intervencionista)

Iliescu

Grines

Herrmann

et al. 2016

Cathet Cardio Intervent

183

135

View full text Add to dashboard Cite

show abstract

“…The occurrence of TC during oncologic treatments is commonly attributed to direct cardiotoxicity of the treatment (mostly via free radicals-induced cardiac myocyte damage and death) [15]. Other hypotheses such as a paraneoplastic phenomenon or a cancer-related stress (either psychological or physical, i.e.…”

Section: Discussionmentioning

confidence: 99%

“…2012 [39]BevacizumabFranco TH, et al Ther Clin Risk Manag 2008 [31]RituximabSmith SA, et al Heart Fail Clin. 2013 [15]Ng KH, et al BMJ Case Rep. 2015 [32]TrastuzumabBurgy M, et al Anticancer Res. 2014 [42]Khanji M, et al Clin Oncol (R Coll Radiol) 2013 [43]Cetuximab, irinotecanKim L, et al J Invasive Cardiol.…”

Section: Discussionmentioning

confidence: 99%

Chemotherapy-induced Takotsubo cardiomyopathy, a case report and review of the literature

et al. 2017

View full text Add to dashboard Cite

BackgroundSeveral chemotherapy molecules, monoclonal antibodies and tyrosine kinase inhibitors, have been linked to Takotsubo cardiomyopathy (TC).Case presentationIn this article, we describe the case of a 45-year-old woman who developed TC after receiving an intra-arterial and intra-venous polychemotherapy for locally advanced epidermoid carcinoma of the anal canal. This is the first described case of TC associated with intra-arterial chemotherapy.ConclusionsA review of the literature points to 5-fluorouracil as the most common molecule associated with TC and highlights the potential risk associated with rechallenging patient with the same drug.

show abstract

“…95 In fact, this entity might be relatively more common among cancer patients given the exposure to various and significant stressors. Moreover, this syndrome has been noted with the use of a number of chemotherapeutics, including 5-FU, capecitabine, cytarabine, axitinib, sunitinib, bevacizumab, rituximab, trastuzumab, and combretastatin.…”

Section: Apical Ballooning Syndrome (“Stress” or “Takotsubo” Cardiomymentioning

confidence: 99%

“…10735 The response to catecholamines might be similarly altered and changes in vasoreactivity might extend to the coronary microcirculation generating the substrate for abnormal perfusion and contraction. 95, 108, 109 Furthermore, a new mechanisms unraveled by chemotherapeutics is the inhibition of PDGF signaling, pericyte function and survival, which influences endothelial cells and cardiac function. 99, 102 Injury to the endothelium and the microvasculature also underlies the ATRA differentiation syndrome, and cardiac stunning has been reported in patients with acute promyelocytic leukemia who are developing this syndrome with retinoic acid treatment.…”

Section: Apical Ballooning Syndrome (“Stress” or “Takotsubo” Cardiomymentioning

confidence: 99%

Vascular Toxicities of Cancer Therapies

et al. 2016

View full text Add to dashboard Cite

Since the late 1990s, there has been a steady decline in cancer-related mortality, in part related to the introduction of so-called “targeted therapies”. Intended to interfere with a specific molecular pathway, these therapies have, paradoxically, led to a number of “off-target” effects. The latest examples are tyrosine kinase inhibitors targeting the Philadelphia Chromosome mutation product, which have been associated with progressive atherosclerosis and acute vascular events. Additionally, agents designed to interfere with the vascular growth factor signaling pathway have vascular side effects ranging from hypertension to arterial events and cardiomyocyte toxicity. Interestingly, the risk of cardiotoxicity with drugs such as trastuzumab is predicted by preexisting cardiovascular risk factors and disease, posing the question of a vascular component to the pathophysiology. The effect on the coronary circulation has been the leading explanation for cardiotoxicity of 5-Fluorouracil and may be the underlying the mechanism of presentation of apical ballooning syndrome with various chemotherapeutics. Classical chemotherapeutics such as cisplatin, often used in combination with bleomycin and vinca alkaloids, can lead to vascular events including acute coronary thrombosis, may be associated with an increased long-term cardiovascular risk. This review is intended to provide an update on the evolving spectrum of vascular toxicities with cancer therapeutics, particularly as it pertains to clinical practice as well as the conceptualization of cardiovascular diseases. Vascular toxicity with cancer therapy: the old and the new, an evolving avenue.

show abstract

Chemotherapy-Induced Takotsubo Cardiomyopathy

Cited by 50 publications

References 42 publications

SCAI Expert consensus statement: Evaluation, management, and special considerations of cardio‐oncology patients in the cardiac catheterization laboratory (endorsed by the cardiological society of india, and sociedad Latino Americana de Cardiologıa intervencionista)

SCAI Expert consensus statement: Evaluation, management, and special considerations of cardio‐oncology patients in the cardiac catheterization laboratory (endorsed by the cardiological society of india, and sociedad Latino Americana de Cardiologıa intervencionista)

Chemotherapy-induced Takotsubo cardiomyopathy, a case report and review of the literature

Vascular Toxicities of Cancer Therapies

Contact Info

Product

Resources

About